Combining Active Pharmaceutical Ingredients: MPT Development & Regulatory Considerations
This fourth webinar in the IMPT’s “Let’s Talk MPTs” series provides product developers and other stakeholders an overview of regulatory considerations for the clinical development of MPTs that combine one or more active pharmaceutical ingredients (APIs), with a focus on products that provide HIV prevention and contraception. Featured discussants were Deven Shah, PhD, and Kevin Hershberger, MBA, from Certara and Tamra Goodrow, PhD, of Deer Run Regulatory Consulting.
View Webinar Recording
Download Presentation
Download Suggested Readings
June 2021
Click for full info +Full Info:
Resource Type:
Citation:
This fourth webinar in the IMPT’s “Let’s Talk MPTs” series provides product developers and other stakeholders an overview of regulatory considerations for the clinical development of MPTs that combine one or more active pharmaceutical ingredients (APIs), with a focus on products that provide HIV prevention and contraception. Featured discussants were Deven Shah, PhD, and Kevin Hershberger, MBA, from Certara and Tamra Goodrow, PhD, of Deer Run Regulatory Consulting.
Authors: The IMPT, Certara, Deven Shah, Kevin Hershberger, Tamra Goodrow
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- MPTs
Topic(s):
- DrugInteractions
- MPTs
- Development
- Trials
- Regulatory
Region(s)
- United States
- Global